HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ITOS

ITeos Therapeutics Inc

Last Close
Jun 13 • 04:00PM ET
10.17
Dollar change
0.00
Percentage change
0.00 		%
Healthcare • Biotechnology • USA • NASD
Peers: MRNA AZN BMY GILD AMGN PFE JNJ REGN VRTX INCY
 | Held by: VTI IWM VXF IWN IBB DFAT SCHA VTWO VHT DFAS
Scroll to Statements
IndexRUT P/E- EPS (ttm)-3.23 Insider Own5.96% Shs Outstand38.27M Perf Week0.00%
Market Cap389.24M Forward P/E- EPS next Y-1.57 Insider Trans100.42% Shs Float35.88M Perf Month33.82%
Income-130.81M PEG- EPS next Q-0.89 Inst Own116.81% Short Float7.06% Perf Quarter38.93%
Sales35.00M P/S11.12 EPS this Y15.74% Inst Trans32.01% Short Ratio2.06 Perf Half Y23.57%
Book/sh14.72 P/B0.69 EPS next Y44.03% ROA-20.30% Short Interest2.53M Perf Year-37.68%
Cash/sh13.60 P/C0.75 EPS next 5Y3.89% ROE-23.68% 52W Range4.80 - 18.13 Perf YTD32.42%
Dividend Est.- P/FCF- EPS past 5Y-34.39% ROIC-23.07% 52W High-43.91% Beta1.51
Dividend TTM- Quick Ratio14.13 Sales past 5Y- Gross Margin96.41% 52W Low111.87% ATR (14)0.40
Dividend Ex-Date- Current Ratio14.13 EPS Y/Y TTM14.60% Oper. Margin-435.19% RSI (14)71.85 Volatility1.05% 4.26%
Employees173 Debt/Eq0.01 Sales Y/Y TTM177.89% Profit Margin-373.75% Recom2.67 Target Price12.83
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q24.92% Payout- Rel Volume0.00 Prev Close10.17
Sales Surprise-100.00% EPS Surprise15.79% Sales Q/Q- EarningsApr 28 AMC Avg Volume1.23M Price10.17
SMA207.30% SMA5031.13% SMA20018.11% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
May-28-25Downgrade Wells Fargo Overweight → Equal Weight $12
May-28-25Downgrade Wedbush Outperform → Neutral $12
May-14-25Downgrade Leerink Partners Outperform → Market Perform $9
May-14-25Downgrade H.C. Wainwright Buy → Neutral
May-13-25Downgrade JP Morgan Overweight → Neutral
Aug-13-24Initiated Wells Fargo Overweight $31
May-05-21Initiated H.C. Wainwright Buy $37
Oct-08-20Initiated Robert W. Baird Outperform $45
Aug-18-20Initiated Wedbush Outperform $45
Aug-18-20Initiated SVB Leerink Outperform $45
Show Previous Ratings
May-30-25 12:00PM
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
(Zacks)
May-29-25 07:59AM
iTeos to shut down following $2bn GSK-partnered TIGIT asset failure
(Pharmaceutical Technology)
May-28-25 08:30AM
iTeos Therapeutics Announces Its Intention to Wind Down Operations
(GlobeNewswire) +17.94%
08:10AM
Cancer drugmaker iTeos to shut down
(BioPharma Dive)
May-15-25 07:55AM
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
(Zacks)
06:00AM Loading…
May-14-25 06:00AM
GSK and iTeos drop anti-TIGIT drug following trial failure
(Clinical Trials Arena)
May-13-25 12:35PM
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
(Benzinga) +13.44%
07:55AM
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
(GlobeNewswire)
07:10AM
iTeos, GSK to shelve TIGIT drug after study setback
(BioPharma Dive)
May-02-25 09:55AM
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
(Zacks)
Apr-28-25 04:30PM
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
(GlobeNewswire)
Mar-25-25 04:35PM
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
(GlobeNewswire) -5.44%
Mar-13-25 09:55AM
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet
(Zacks)
Mar-05-25 07:00AM
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
(GlobeNewswire) +5.99%
Jan-13-25 12:00PM
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
(Zacks)
07:00AM Loading…
Jan-10-25 07:00AM
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
(GlobeNewswire)
Jan-08-25 07:00AM
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-20-24 07:20AM
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo
(TipRanks)
Dec-13-24 01:25PM
Inupadenant deprioritised by iTeos in favour of pipeline TIGIT therapy
(Clinical Trials Arena)
Dec-12-24 08:55AM
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
(GlobeNewswire)
Nov-26-24 07:00AM
iTeos to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Nov-12-24 07:00AM
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
Oct-24-24 07:00AM
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
(GlobeNewswire)
Oct-16-24 01:01AM
BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc
(GuruFocus.com)
Sep-30-24 01:01PM
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc
(GuruFocus.com)
Sep-16-24 04:04PM
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
(Investor's Business Daily) -27.54%
Sep-15-24 09:12PM
ESMO 2024: TIGIT race tightens with first look at GSK/iTeoss TIGIT in NSCLC
(Pharmaceutical Technology)
Sep-14-24 08:10AM
TIGIT drug from iTeos shrinks lung tumors in trial
(BioPharma Dive)
02:30AM
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
(GlobeNewswire)
Aug-28-24 04:30PM
iTeos to Participate in Upcoming Investor Conferences
(GlobeNewswire)
08:30AM Loading…
Aug-20-24 08:30AM
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
(GlobeNewswire) +10.13%
Aug-08-24 08:20AM
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
07:00AM
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
Aug-05-24 07:00AM
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
(GlobeNewswire)
Jul-09-24 12:33PM
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial
(Pharmaceutical Technology)
Jul-08-24 07:00AM
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
(GlobeNewswire)
Jun-18-24 06:33AM
iTeos Therapeutics and GSK begin Phase III trial of combination therapy for NSCLC
(Clinical Trials Arena)
Jun-17-24 09:00AM
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
(GlobeNewswire) -6.04%
May-13-24 08:28AM
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating
(MT Newswires)
May-10-24 01:53PM
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024
(InvestorPlace) +43.07%
12:21PM
Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating
(MT Newswires)
09:40AM
iTeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump
(MT Newswires)
08:26AM
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
08:24AM
iTeos Therapeutics Announces $120 Million Registered Direct Offering
(GlobeNewswire)
08:09AM
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
(BioPharma Dive)
Apr-07-24 04:30PM
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
(GlobeNewswire)
Mar-06-24 02:51PM
ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q4 2023
(InvestorPlace) +7.80%
07:01AM
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
(GlobeNewswire)
07:00AM
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Mar-05-24 04:30PM
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
(GlobeNewswire)
Mar-01-24 07:00AM
iTeos to Participate in Upcoming Investor Conferences
(GlobeNewswire) +5.23%
Feb-26-24 06:11AM
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
(Zacks)
Jan-08-24 07:00AM
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
(GlobeNewswire)
Jan-03-24 07:00AM
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-13-23 09:55AM
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade
(Zacks)
Nov-27-23 09:55AM
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
(Zacks) -5.44%
Nov-21-23 07:00AM
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
(GlobeNewswire)
Nov-13-23 09:55AM
Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher
(Zacks)
Nov-10-23 09:55AM
Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know
(Zacks)
Nov-07-23 07:00AM
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Oct-31-23 03:01AM
Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?
(Zacks) +7.48%
Oct-16-23 01:46PM
Hedge Fund and Insider Trading News: Ken Griffin, EcoR1 Capital, Glen Point Capital, JAT Capital, Eisler Capital, Elliott Management, iTeos Therapeutics Inc (ITOS), Funko, Inc. (FNKO), and More
(Insider Monkey)
04:38AM
iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?
(Zacks)
Oct-11-23 05:55PM
NCR Atleos Set to Join S&P SmallCap 600
(PR Newswire) -6.72% -6.39%
Sep-06-23 07:00AM
iTeos to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-26-23 11:02AM
BOXER CAPITAL, LLC Reduces Stake in ITeos Therapeutics Inc
(GuruFocus.com)
Aug-24-23 11:30AM
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak
(Zacks)
Aug-23-23 04:10PM
Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22%
(Investor's Business Daily) +14.89%
02:00PM
Watertown biotech shares spike after accidental data publication at Roche
(American City Business Journals)
09:24AM
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
(Investor's Business Daily)
Aug-08-23 07:00AM
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Jun-21-23 08:00PM
ITOS: Lowering target price to $11.00
(Argus Research)
May-13-23 08:03AM
Broker Revenue Forecasts For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Are Surging Higher
(Simply Wall St.)
May-11-23 06:11AM
iTeos Therapeutics First Quarter 2023 Earnings: Beats Expectations
(Simply Wall St.)
May-10-23 08:35AM
ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
07:01AM
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
May-05-23 08:51AM
iTeos Therapeutics (NASDAQ:ITOS) shareholders have endured a 46% loss from investing in the stock a year ago
(Simply Wall St.)
Apr-26-23 08:00PM
ITOS: What does Argus have to say about ITOS?
(Argus Research)
Mar-23-23 01:56PM
Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore
(TipRanks)
Mar-21-23 06:07AM
Take Care Before Jumping Onto iTeos Therapeutics, Inc. (NASDAQ:ITOS) Even Though It's 25% Cheaper
(Simply Wall St.)
Mar-17-23 06:18AM
Time To Worry? Analysts Are Downgrading Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Outlook
(Simply Wall St.)
Mar-15-23 08:35AM
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates
(Zacks)
07:00AM
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
(GlobeNewswire)
Feb-28-23 07:00AM
iTeos to Present at Cowen 43rd Annual Health Care Conference
(GlobeNewswire)
Feb-07-23 01:51PM
The 7 Best Biotech Stocks to Buy for February 2023
(InvestorPlace)
07:00AM
iTeos to Present at SVB Securities Global Biopharma Conference
(GlobeNewswire)
Feb-02-23 02:19PM
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
(InvestorPlace)
Jan-09-23 07:00AM
iTeos Provides Business Updates and Clinical Development Plans for 2023
(GlobeNewswire)
Jan-03-23 07:00AM
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) -5.07%
Dec-07-22 08:07AM
Could The Market Be Wrong About iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Its Attractive Financial Prospects?
(Simply Wall St.)
Nov-22-22 07:00AM
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
(GlobeNewswire) -5.98%
Nov-10-22 07:55PM
ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates
(Zacks) +11.14%
04:01PM
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
(GlobeNewswire)
Nov-04-22 05:46PM
Top Biotech Stocks for Q4 2022
(Investopedia)
Nov-02-22 10:00AM
ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
(Zacks)
Oct-18-22 08:36AM
Shareholders in iTeos Therapeutics (NASDAQ:ITOS) are in the red if they invested a year ago
(Simply Wall St.)
Aug-12-22 06:16AM
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Cut Their EPS Forecasts Substantially
(Simply Wall St.) +7.00%
Aug-10-22 05:25PM
ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates
(Zacks) -12.51%
04:01PM
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire)
Aug-02-22 07:00AM
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
(GlobeNewswire)
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Detheux MichelChief Executive OfficerJun 10 '25Option Exercise4.30137,910593,01394,027Jun 11 09:01 PM
Detheux MichelChief Executive OfficerJun 09 '25Option Exercise4.3043,882188,69343,882Jun 11 09:01 PM
Detheux MichelChief Executive OfficerJun 10 '25Option Exercise4.3026,400113,520153,903Jun 11 09:01 PM
Detheux MichelChief Executive OfficerJun 09 '25Option Exercise4.308,40036,120144,303Jun 11 09:01 PM
Detheux MichelChief Executive OfficerJun 09 '25Sale10.0343,882440,1360Jun 11 09:01 PM
Detheux MichelChief Executive OfficerJun 10 '25Sale10.0243,883439,7080Jun 11 09:01 PM
Detheux MichelChief Executive OfficerJun 09 '25Sale10.038,40084,252135,903Jun 11 09:01 PM
Detheux MichelChief Executive OfficerJun 10 '25Sale10.028,40084,168135,903Jun 11 09:01 PM
Detheux MichelOfficerJun 10 '25Proposed Sale10.0252,283523,876Jun 10 04:19 PM
Detheux MichelOfficerJun 09 '25Proposed Sale10.1752,282531,708Jun 09 04:12 PM
Detheux MichelChief Executive OfficerJun 04 '25Option Exercise4.3043,883188,69743,883Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 06 '25Option Exercise4.3043,882188,69343,882Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 05 '25Option Exercise4.3043,882188,69343,882Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 05 '25Option Exercise4.308,40036,120144,303Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 04 '25Option Exercise4.308,40036,120144,303Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 06 '25Option Exercise4.308,40036,120144,303Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 06 '25Sale10.2143,882448,0350Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 05 '25Sale10.1543,882445,4020Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 04 '25Sale10.1043,883443,2180Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 06 '25Sale10.218,40085,764135,903Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 05 '25Sale10.158,40085,260135,903Jun 06 09:03 PM
Detheux MichelChief Executive OfficerJun 04 '25Sale10.108,40084,840135,903Jun 06 09:03 PM
Hallal DavidDirectorJun 06 '25Option Exercise4.3038,228164,38038,228Jun 06 09:03 PM
Hallal DavidDirectorJun 04 '25Option Exercise4.3038,227164,37638,227Jun 06 09:03 PM
Hallal DavidDirectorJun 05 '25Option Exercise4.3038,227164,37638,227Jun 06 09:03 PM
Hallal DavidDirectorJun 06 '25Sale10.2438,228391,4550Jun 06 09:03 PM
Hallal DavidDirectorJun 05 '25Sale10.1538,227388,0040Jun 06 09:03 PM
Hallal DavidDirectorJun 04 '25Sale10.0738,227384,9460Jun 06 09:03 PM
Detheux MichelOfficerJun 06 '25Proposed Sale10.1952,282532,754Jun 06 04:11 PM
DAVID L HALLALDirectorJun 06 '25Proposed Sale10.2438,228391,489Jun 06 04:09 PM
DAVID L HALLALDirectorJun 05 '25Proposed Sale10.1538,227388,103Jun 05 04:27 PM
Detheux MichelOfficerJun 05 '25Proposed Sale10.2252,282534,322Jun 05 04:10 PM
Detheux MichelOfficerJun 04 '25Proposed Sale10.0652,283525,967Jun 04 04:03 PM
DAVID L HALLALDirectorJun 04 '25Proposed Sale10.0738,227384,782Jun 04 04:03 PM
EcoR1 Capital, LLC10% OwnerMay 15 '25Buy8.003,300,00026,400,00010,688,978May 16 06:52 PM
EcoR1 Capital, LLC10% OwnerMay 14 '25Buy7.411,658,97812,285,5627,388,978May 16 06:52 PM
GADICKE ANSBERTFormer 10% OwnerMay 13 '25Sale8.061,031,9318,317,3643,452,797May 15 05:34 PM
MPM BIOVENTURES 2018, L.P.Former 10% OwnerMay 13 '25Sale8.06630,1915,079,3392,108,594May 15 05:33 PM
MPM BioVentures 2014, L.P.Former 10% OwnerMay 13 '25Sale8.06630,1915,079,3392,108,594May 15 05:32 PM
Van Hauwermeiren TimothyDirectorMay 13 '25Option Exercise4.3022,34696,08822,346May 14 08:00 PM
Gall MatthewChief Financial OfficerNov 19 '24Buy7.735,00038,63565,429Nov 19 07:59 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.